FindTrial
Sign In

olvimulogene nanivacirepvec

BIOLOGICAL2 trials

Sponsors

Genelux Corporation

Conditions

Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaEndometrioid Ovarian CancerFallopian Tube CancerHigh-grade Serous Ovarian CancerMetastatic Non-squamous Non Small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung Cancer

Phase 2

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
RecruitingNCT06463665
Genelux CorporationAdvanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer +5
Start: 2024-09-26End: 2029-07-01Target: 142Updated: 2026-06-04

Phase 3

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
RecruitingNCT05281471
Genelux CorporationEndometrioid Ovarian Cancer, Fallopian Tube Cancer, High-grade Serous Ovarian Cancer +4
Start: 2022-08-31End: 2027-12-01Target: 186Updated: 2026-08-26

Related Papers

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
2023-09-0413 citations
TP026/#1435 Phase 3 study of efficacy & safety of Olvi-Vec and platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in platinum-resistant/refractory ovarian cancer (ONPRIME; GOG-3076) [NCT05281471]
2022-12-011 citations